Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Skin and subcutaneous tissue disorders

  • 863 clinical trials
  • 267 recruiting
  • 360 conditions
  • 25 countries

Conditions in this area

360 conditions with trials, the busiest first

Dermatitis atopic92Malignant melanoma80Systemic lupus erythematosus65Psoriasis54Hidradenitis47Psoriatic arthropathy46Systemic scleroderma41Metastatic malignant melanoma32Vitiligo24Hereditary angioedema22Chronic spontaneous urticaria19Malignant melanoma stage III17Dermatomyositis16Non-small cell lung cancer16Alopecia areata15Cutaneous lupus erythematosus15Rheumatoid arthritis14Diabetic foot13Basal cell carcinoma12Hepatocellular carcinoma12Malignant melanoma stage IV12Actinic keratosis11Neurodermatitis11Squamous cell carcinoma of skin11+336

Clinical trials in Skin and subcutaneous tissue disorders

863 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

863 clinical trials

Papulopustular rosacea

Recruiting

Efficacy and safety of remibrutinib (LOU064) in adult patients with papulopustular rosacea: a randomized, double‑blind, placebo‑controlled Phase 2 trial

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Dermatitis atopic

Recruiting

Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Face and Neck Atopic Dermatitis

Registered drug
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Almirall S.A.

Systemic scleroderma

Recruiting

Phase 2 Study of Nemolizumab for Skin Thickening in Adults with Systemic Sclerosis

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Nemolizumab
  • Sponsor:Galderma S.A.

Alopecia areata

Recruiting

A Phase 2a Study of ly4005130 in Adults with Severe Alopecia Areata

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:LY4005130
  • Sponsor:Eli Lilly & Co.

Systemic lupus erythematosus

Recruiting

Evaluation of Anifrolumab Subcutaneous Treatment in Immunosuppressant‑Naïve and Biologic‑Naïve Patients with Systemic Lupus Erythematosus

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

Vitiligo

Recruiting

Efficacy and Safety of LY4005130 Compared with Placebo in Adults with Non‑Segmental Vitiligo

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:LY4005130
  • Sponsor:Eli Lilly & Co.

Hidradenitis

Recruiting

Long-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Psoriatic arthropathy

Recruiting

Long-Term Safety and Efficacy of Zasocitinib in Adults with Active Psoriatic Arthritis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.

Systemic lupus erythematosus

Recruiting

BI 3000202 in Patients with Moderate to Severe Systemic Lupus Erythematosus

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:BI 3000202
  • Sponsor:Boehringer Ingelheim Espana S.A.

Cold urticaria

Recruiting

A study to evaluate the effectiveness of barzolvolimab in participants with cold urticaria and symptomatic dermographism

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Epinephrine
  • Sponsor:Celldex Therapeutics Inc.

Alopecia areata

Recruiting

A study to evaluate the effectiveness and safety of LAD603 in adults with severe to very severe alopecia areata

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:LAD603
  • Sponsor:Almirall S.A.

Substances studied in this area

The therapies tested most often in Skin and subcutaneous tissue disorders trials.

Pembrolizumab57 clinical trialsNivolumab33 clinical trialsSodium Chloride21 clinical trialsDeucravacitinib19 clinical trialsCemiplimab18 clinical trialsUpadacitinib17 clinical trialsIpilimumab15 clinical trialsRemibrutinib13 clinical trialsRituximab13 clinical trials
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.